Multivariate analyses for CXXC5 expression
| Variable* . | OR/HR . | 95% CI . | P . |
|---|---|---|---|
| Relapse rate | |||
| Low CXXC5† | 0.5 | 0.3-0.8 | .007 |
| Cytogenetic risk | 1.9 | 1.2-2.9 | .005 |
| WBC | 1.06 | 1.0-1.1 | .005 |
| CEBPA mut., biallelic | 0.4 | 0.2-1.0 | .05 |
| ASXL1 mut. | 9.5 | 2.0-45 | .004 |
| Overall survival | |||
| Low CXXC5† | 0.6 | 0.5-0.8 | .001 |
| Cytogenetic risk | 1.7 | 1.3-2.1 | <.001 |
| Age | 1.2 | 1.0-1.3 | .004 |
| FLT3-ITD/NPM1 wt | 1.7 | 1.2-2.5 | .004 |
| NPM1 mut./FLT3-ITD neg. | 0.6 | 0.4-0.8 | .006 |
| CEBPA mut., biallelic | 0.3 | 0.2-0.6 | <.001 |
| DNMT3A mut. | 1.4 | 1.1-2.0 | .02 |
| ASXL1 mut. | 1.6 | 1.0-2.5 | .04 |
| Event-free survival | |||
| Low CXXC5† | 0.6 | 0.5-0.8 | <.001 |
| Cytogenetic risk | 1.6 | 1.3-2.0 | <.001 |
| WBC | 1.02 | 1.0-1.0 | .04 |
| FLT3-ITD/NPM1 wt | 1.7 | 1.2-2.5 | .006 |
| NPM1 mut./FLT3-ITD neg. | 0.6 | 0.4-0.9 | .009 |
| CEBPA mut., biallelic | 0.3 | 0.2-0.6 | <.001 |
| DNMT3A mut. | 1.4 | 1.0-1.8 | .04 |
| ASXL1 mut. | 2.0 | 1.2-3.2 | .005 |
| Variable* . | OR/HR . | 95% CI . | P . |
|---|---|---|---|
| Relapse rate | |||
| Low CXXC5† | 0.5 | 0.3-0.8 | .007 |
| Cytogenetic risk | 1.9 | 1.2-2.9 | .005 |
| WBC | 1.06 | 1.0-1.1 | .005 |
| CEBPA mut., biallelic | 0.4 | 0.2-1.0 | .05 |
| ASXL1 mut. | 9.5 | 2.0-45 | .004 |
| Overall survival | |||
| Low CXXC5† | 0.6 | 0.5-0.8 | .001 |
| Cytogenetic risk | 1.7 | 1.3-2.1 | <.001 |
| Age | 1.2 | 1.0-1.3 | .004 |
| FLT3-ITD/NPM1 wt | 1.7 | 1.2-2.5 | .004 |
| NPM1 mut./FLT3-ITD neg. | 0.6 | 0.4-0.8 | .006 |
| CEBPA mut., biallelic | 0.3 | 0.2-0.6 | <.001 |
| DNMT3A mut. | 1.4 | 1.1-2.0 | .02 |
| ASXL1 mut. | 1.6 | 1.0-2.5 | .04 |
| Event-free survival | |||
| Low CXXC5† | 0.6 | 0.5-0.8 | <.001 |
| Cytogenetic risk | 1.6 | 1.3-2.0 | <.001 |
| WBC | 1.02 | 1.0-1.0 | .04 |
| FLT3-ITD/NPM1 wt | 1.7 | 1.2-2.5 | .006 |
| NPM1 mut./FLT3-ITD neg. | 0.6 | 0.4-0.9 | .009 |
| CEBPA mut., biallelic | 0.3 | 0.2-0.6 | <.001 |
| DNMT3A mut. | 1.4 | 1.0-1.8 | .04 |
| ASXL1 mut. | 2.0 | 1.2-3.2 | .005 |
CI, confidence interval; HR, hazard ratio; mut., mutated; neg., negative; OR, odds ratio; WBC, white blood cell count; wt, wild-type.
Variables considered for model inclusion were (see supplemental Material for details): CXXC5 expression (below vs above median level), cytogenetic risk groups (good, intermediate, unfavorable), age (10-year increase), WBC (10/nl increase), FLT3-ITD34 /NPM1 wild-type (present vs absent), NPM1 mutation35 /FLT3-ITD negative (present vs absent), CEBPA biallelic mutation36 (present vs absent), DNMT3A mutation37 (present vs absent), ASXL1 mutation38 (present vs absent), WT1 mutation (present vs absent), WT1 expression (lower vs higher than median).
Below median expression level.